Canada Markets closed

Iterum Therapeutics plc (ITRM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.1993-0.0046 (-2.26%)
At close: 04:00PM EDT
0.2051 +0.01 (+2.91%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.2039
Open0.2000
Bid0.2050 x 1300
Ask0.2069 x 1200
Day's Range0.1976 - 0.2145
52 Week Range0.1750 - 2.5200
Volume1,313,281
Avg. Volume1,122,485
Market Cap36.427M
Beta (5Y Monthly)1.07
PE Ratio (TTM)N/A
EPS (TTM)-0.7690
Earnings DateMar 10, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    DUBLIN, Ireland and CHICAGO, June 14, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has granted a non-statutory share option to purchase an aggregate of 35,000 ordinary shares of the Company as an inducement to a newly hired employee. Th

  • GlobeNewswire

    Iterum Therapeutics Reports First Quarter 2022 Financial Results

    -General Alignment with FDA on Key Aspects of Design of Proposed Additional Clinical Trial- -Cash Runway into 2024- DUBLIN, Ireland and CHICAGO, May 13, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March

  • GlobeNewswire

    Iterum Therapeutics Provides Regulatory Update

    DUBLIN, Ireland and CHICAGO, May 11, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced it met with the US Food and Drug Administration (“FDA”) on May 5, 2022, to discuss its proposed plan to conduct one additional Phase 3 clinical trial to support t